EMA Grants PRIME Designation to TolerogenixX's MIC-Lx Cell Therapy for Kidney Transplant Tolerance
Key Insights
The European Medicines Agency (search) has granted PRIME designation to TolerogenixX (search)'s MIC-Lx therapy, a personalized cell therapy designed to induce donor-specific immune tolerance in kidney transplant recipients.
Clinical data from Phase I and ongoing Phase II studies with up to 10-year follow-up demonstrate absence of donor-specific antibody responses, substantial reduction of immunosuppressive therapy, and fewer opportunistic infections.
The therapy aims to address the significant unmet need for kidney transplant patients who currently require life-long immunosuppressive therapy associated with infections, malignancies, and metabolic complications.
TolerogenixX (search), a clinical-stage biopharmaceutical company, announced that the European Medicines Agency (search) (EMA) has granted PRIority MEdicines (PRIME) designation to its lead cell therapy candidate MIC-Lx for individualized immunosuppression in living donor kidney transplantation. The designation recognizes therapies addressing serious diseases with significant unmet medical need and provides enhanced regulatory interaction to accelerate clinical development and patient access.
Addressing Critical Transplantation Challenges
Kidney transplantation represents the preferred treatment for end-stage renal disease (search), yet patients face the burden of life-long systemic immunosuppressive therapy to prevent organ rejection. These treatments carry significant risks, including infections, malignancies, and metabolic complications. TolerogenixX (search)'s MIC-Lx therapy (Modified Immune Cells for Living-donor transplants) aims to induce donor-specific immune tolerance, potentially allowing transplant recipients to significantly reduce chronic immunosuppression.
The PRIME designation follows a positive assessment by the Committee for Advanced Therapies (CAT) and endorsement by the Committee for Medicinal Products for Human Use (CHMP) during its February 2026 meeting. According to the EMA assessment, available clinical and non-clinical data support the hypothesis that modified donor immune cells treated with a cytostatic agent may induce a tolerogenic immune state in transplant recipients.
Compelling Long-Term Clinical Evidence
Clinical Phase I and ongoing Phase II studies in renal transplant patients with follow-up data of up to 10 years support the proposed mechanism of action. The studies demonstrate three key outcomes: absence of donor-specific antibody responses, substantial reduction of immunosuppressive therapy, and fewer opportunistic infections.
Five-year follow-up data from the Phase I study, published in Frontiers in Immunology in 2023, showed long-lasting donor-specific immune modulation accompanied by a sustained increase in regulatory B lymphocytes (search). The company's lead candidate MIC-Lx has completed a Phase Ib clinical trial (TOL-1) in kidney transplant recipients, demonstrating sustained safety and tolerability after a single administration while preserving normal immune responses.
Innovative Manufacturing and Scalability
MIC treatment represents a personalized cell therapy approach designed to modulate the immune system through a novel mode of action to achieve specific and sustained immune tolerance. The therapy's production process offers significant advantages: using cells obtained by leukapheresis, MIC can be manufactured within 24 hours. Due to a standardized procedure, MIC production can be scaled up easily and made available globally using TolerogenixX (search)'s proprietary approach.
"The EMA PRIME designation is an important recognition of the potential of our MIC technology to improve the current treatment paradigm in transplantation," said Prof. Dr. Matthias Schaier, CEO of TolerogenixX (search). "Our goal is to enable donor-specific immune tolerance and reduce the burden of chronic immunosuppression for transplant patients. Clinical data generated so far indicate that our MIC therapy may provide an effective treatment option for kidney transplant recipients while reducing the side effects typically associated with long-term immunosuppression."
Broader Therapeutic Potential
Beyond transplantation, MIC treatment could benefit patients with autoimmune diseases such as systemic lupus erythematosus (search) and multiple sclerosis (search). TolerogenixX (search), founded in 2016 and headquartered in Heidelberg, Germany, develops novel, personalized therapies to induce antigen-specific immune tolerance in transplantation and autoimmune diseases.
A Phase IIb study (TOL-2) is currently ongoing, with the company planning to publish data from this trial in the first half of 2027. The proprietary MIC technology aims to modulate the immune system in a targeted manner, potentially reducing the need for long-term systemic immunosuppression across multiple therapeutic areas.